210 related articles for article (PubMed ID: 33528025)
1. Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nation-wide policy change evaluation study in the Netherlands.
Luken JS; Folman CC; Lukens MV; Meekers JH; Ligthart PC; Schonewille H; Zwaginga JJ; Janssen MP; van der Schoot CE; van der Bom JG; de Haas M
Transfusion; 2021 Mar; 61(3):713-721. PubMed ID: 33528025
[TBL] [Abstract][Full Text] [Related]
2. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
[TBL] [Abstract][Full Text] [Related]
3. [Hemolytic disease of the newborn and irregular blood group antibodies in the Netherlands: prevalence and morbidity].
van Dijk BA; Hirasing RA; Overbeeke MA
Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1465-9. PubMed ID: 10443262
[TBL] [Abstract][Full Text] [Related]
4. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
5. The significance of anti-Kell sensitization in pregnancy.
Mayne KM; Bowell PJ; Pratt GA
Clin Lab Haematol; 1990; 12(4):379-85. PubMed ID: 2081378
[TBL] [Abstract][Full Text] [Related]
6. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations.
Hendrickson JE; Delaney M
Transfus Med Rev; 2016 Oct; 30(4):159-64. PubMed ID: 27397673
[TBL] [Abstract][Full Text] [Related]
7. [Prevention, diagnosis and treatment of blood group immunization during pregnancy].
van Aken WG; Christiaens GC
Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2507-10. PubMed ID: 10627751
[TBL] [Abstract][Full Text] [Related]
8. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus.
Schonewille H; Klumper FJ; van de Watering LM; Kanhai HH; Brand A
Am J Obstet Gynecol; 2007 Feb; 196(2):143.e1-6. PubMed ID: 17306657
[TBL] [Abstract][Full Text] [Related]
9. The effect of extended c, E and K matching in females under 45 years of age on the incidence of transfusion-induced red blood cell alloimmunisation.
Oud JA; Evers D; de Haas M; de Vooght KMK; van de Kerkhof D; Som N; Péquériaux NCV; Hudig F; Albersen A; van der Bom JG; Zwaginga JJ
Br J Haematol; 2021 Nov; 195(4):604-611. PubMed ID: 34346067
[TBL] [Abstract][Full Text] [Related]
10. Kell alloimmunization, hemolytic disease of the newborn, and perinatal management.
Wenk RE; Goldstein P; Felix JK
Obstet Gynecol; 1985 Oct; 66(4):473-6. PubMed ID: 3931011
[TBL] [Abstract][Full Text] [Related]
11. [Management of feto-maternal red cell allo-immunizations].
Bricca P; Guinchard E; Guitton Bliem C
Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
[TBL] [Abstract][Full Text] [Related]
12. Provision of KEL1-negative blood to obstetric patients: a 3-year single-institution retrospective review.
O'Brien KL; Kim YA; Haspel RL; Uhl L
Transfusion; 2015 Mar; 55(3):599-604; quiz 598. PubMed ID: 25118004
[TBL] [Abstract][Full Text] [Related]
13. Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model.
Stowell SR; Henry KL; Smith NH; Hudson KE; Halverson GR; Park JC; Bennett AM; Girard-Pierce KR; Arthur CM; Bunting ST; Zimring JC; Hendrickson JE
Blood; 2013 Aug; 122(8):1494-504. PubMed ID: 23801629
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy.
Koelewijn JM; Vrijkotte TG; de Haas M; van der Schoot CE; Bonsel GJ
BJOG; 2009 Apr; 116(5):655-64. PubMed ID: 19210505
[TBL] [Abstract][Full Text] [Related]
15. KEL1 negative red cell transfusions for females of current or future child-bearing potential: A clinical impact and feasibility study.
Ning S; Morin PA; Elahie A; Li N; Liu Y; Barty R; Clarke G; Zeller M; Heddle NM
Transfusion; 2023 Jan; 63(1):59-68. PubMed ID: 36519693
[TBL] [Abstract][Full Text] [Related]
16. Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens?
Schonewille H; Brand A
Transfusion; 2008 May; 48(5):958-63. PubMed ID: 18454736
[TBL] [Abstract][Full Text] [Related]
17. Erythroblastosis fetalis produced by anti-k.
Bowman JM; Harman FA; Manning CR; Pollock JM
Vox Sang; 1989; 56(3):187-9. PubMed ID: 2728396
[TBL] [Abstract][Full Text] [Related]
18. Frequency and specificity of red cell antibodies in thalassemia patients in Albania.
Seferi I; Xhetani M; Face M; Burazeri G; Nastas E; Vyshka G
Int J Lab Hematol; 2015 Aug; 37(4):569-74. PubMed ID: 25865362
[TBL] [Abstract][Full Text] [Related]
19. Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study.
Liu S; Ajne G; Wikman A; Lindqvist C; Reilly M; Tiblad E
Acta Obstet Gynecol Scand; 2021 Dec; 100(12):2216-2225. PubMed ID: 34476807
[TBL] [Abstract][Full Text] [Related]
20. The clinical outcome of non-RhD antibody affected pregnancies in Northern Ireland.
Chandrasekar A; Morris KG; Tubman TR; Tharma S; McClelland WM
Ulster Med J; 2001 Nov; 70(2):89-94. PubMed ID: 11795772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
